Adicet Bio Shares Active Pre-Market Ahead of Phase 1 Prula-cel Lupus Data

Adicet Bio Inc. (ACET) shares traded actively in pre-market on September 28, 2026, ahead of the company's planned release of Phase 1 clinical data for prulacabtagene leucel (prula-cel) in systemic lupus erythematosus (SLE), with or without lupus nephritis (LN). The data update covers the company's lead CAR-T candidate targeting autoimmune indications. No specific efficacy or safety figures were disclosed in the advance notice. Investors are monitoring the results as a key catalyst for the clinical program. The timing of the full data release was not specified.